drugset / Trial / NCT04885426
Metformin for the Prevention of CRA Recurrence
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2022-11
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 250 mg | — |
| Subject | Metformin | Small molecule | 500 mg | — |